A Novel Model to Combine Clinical and Pathway-Based Transcriptomic Information for the Prognosis Prediction of Breast Cancer

PLoS Computational Biology

Volumn 10, Issue 9, 2014, Pages

  Huang, Sijia ^a,b   Yee, Cameron ^c   Ching, Travers ^a,b   Yu, Herbert ^b   Garmire, Lana X ^a,b  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; DISEASES; FORECASTING; GENE EXPRESSION;

BREAST CANCER; BREAST CANCER PROGNOSIS; CLINICAL INFORMATION; DATA SET; GENOMIC INFORMATION; GENOMICS; P-VALUES; PERFORMANCE; PROGNOSIS PREDICTION; TESTING DATA;

GENOME;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; GENE EXPRESSION; GENE MUTATION; GENETIC MODEL; HUMAN; INFORMATION PROCESSING; L1 LASSO PENALIZATION METHOD; LYMPH NODE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PATHWAY BASED GENOMIC MODEL; PATHWAY DEREGULATION SCORE; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; SENSITIVITY ANALYSIS; TRANSCRIPTOMICS; TUMOR GENE; VALIDATION STUDY; ALGORITHM; BREAST TUMOR; DISEASE COURSE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL;

TRANSCRIPTOME;

ALGORITHMS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; TRANSCRIPTOME;

EID: 84907588668     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003851     Document Type: Article

References (54)

1. Society AC (2013) Cancer Facts & Figures 2013. Atlanta: American Cancer Society.
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492–2502.
3. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, et al. (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16: 6100–6110.
4. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, et al. (2012) Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev 21: 1848–1855.
5. Cancer Genome Atlas N, (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70.
6. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671–679.
7. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999–2009.
8. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536.
9. Abraham G, Kowalczyk A, Loi S, Haviv I, Zobel J, (2010) Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. BMC Bioinformatics 11: 277.
10. van den Akker EB, Passtoors WM, Jansen R, van Zwet EW, Goeman JJ, et al. (2013) Meta-analysis on blood transcriptomic studies identifies consistently coexpressed protein-protein interaction modules as robust markers of human aging. Aging Cell 13: 216–25 doi:10.1111/acel.12160
11. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, et al. (2008) A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 10: R93.
12. Teschendorff AE, Gomez S, Arenas A, El-Ashry D, Schmidt M, et al. (2010) Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer 10: 604.
13. Ma S, Kosorok MR, Huang J, Dai Y, (2011) Incorporating higher-order representative features improves prediction in network-based cancer prognosis analysis. BMC Med Genomics 4: 5.
14. Lee E, Chuang HY, Kim JW, Ideker T, Lee D, (2008) Inferring pathway activity toward precise disease classification. PLoS Comput Biol 4: e1000217.
15. Efron B, Tibshirani R, (2007) On Testing the Significance of Sets of Genes. Annals of Applied Statistics 1: 107–129.
16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–15550.
17. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353–357.
18. van Vliet MH, Horlings HM, van de Vijver MJ, Reinders MJ, Wessels LF, (2012) Integration of clinical and gene expression data has a synergetic effect on predicting breast cancer outcome. PLoS One 7: e40358.
19. Miller LD, Smeds J, George J, Vega VB, Vergara L, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550–13555.
20. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, et al. (2012) A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 18: 4465–4472.
21. Fan C, Prat A, Parker JS, Liu Y, Carey LA, et al. (2011) Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics 4: 3.
22. Ivshina AV, George J, Senko O, Mow B, Putti TC, et al. (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292–10301.
23. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953–964.
24. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, et al. (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207–3214.
25. Drier Y, Sheffer M, Domany E, (2013) Pathway-based personalized analysis of cancer. Proc Natl Acad Sci U S A 110: 6388–6393.
26. Gill RD, (1992) Multistate life-tables and regression models. Math Popul Stud 3: 259–276.
27. Tibshirani R, (1997) The lasso method for variable selection in the Cox model. Stat Med 16: 385–395.
28. Tibshirani R, (2011) Regression shrinkage and selection via the lasso: a retrospective. Journal of the Royal Statistical Society Series B (Statistical Methodology) 73: 273–282.
29. Goeman JJ, (2009) L1 penalized estimation in the Cox proportional hazards model. Biom J 52: 70–84.
30. Sveen A, Agesen TH, Nesbakken A, Meling GI, Rognum TO, et al. (2012) ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res 18: 6001–6010.
31. Yong H-Y, Hwang J-S, Son H, Park H-I, Oh E-S, et al. (2011) Identification of H-Ras-Specific Motif for the Activation of Invasive Signaling Program in Human Breast Epithelial Cells. Neoplasia (New York, NY) 13: 98–107.
32. Tian S, Simon I, Moreno V, Roepman P, Tabernero J, et al. (2013) A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 62: 540–549.
33. Fu M, Maresh EL, Helguera G, Kiyohara M, Qin Y, et al. (2014) Rationale and pre-clinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13: 902–15 doi:10.1158/1535-7163.MCT-13-0199
34. Valdehita A, Bajo AM, Fernández-Martínez AB, Arenas MI, Vacas E, et al. (2010) Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Peptides 31: 2035–2045.
35. Lee KH, Ho WY, Wu SJ, Omar HA, Huang PJ, et al. (2014) Modulation of Cyclins, p53 and Mitogen-Activated Protein Kinases Signaling in Breast Cancer Cell Lines by 4-(3,4,5-Trimethoxyphenoxy)benzoic Acid. Int J Mol Sci 15: 743–757.
36. Pham TT, Angus SP, Johnson GL, (2013) MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis. Genes & cancer 4: 419–426.
37. Tao MH, Mason JB, Marian C, McCann SE, Platek ME, et al. (2011) Promoter methylation of E-cadherin, p16, and RAR-beta(2) genes in breast tumors and dietary intake of nutrients important in one-carbon metabolism. Nutr Cancer 63: 1143–1150.
38. Rubino D, Driggers P, Arbit D, Kemp L, Miller B, et al. (1998) Characterization of Brx, a novel Dbl family member that modulates estrogen receptor action. Oncogene 16: 2513–2526.
39. Driggers PH, Segars JH, Rubino DM, (2001) The proto-oncoprotein Brx activates estrogen receptor beta by a p38 mitogen-activated protein kinase pathway. J Biol Chem 276: 46792–46797.
40. Guille A, Chaffanet M, Birnbaum D, (2013) Signaling pathway switch in breast cancer. Cancer cell international 13: 66.
41. Puig T, Vázquez-Martín A, Relat J, Pétriz J, Menéndez JA, et al. (2008) Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast cancer research and treatment 109: 471–479.
42. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, et al. (2005) Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clinical cancer research: an official journal of the American Association for Cancer Research 11: 7392–7397.
43. Engelmann D, Pützer BM, (2012) The Dark Side of E2F1: In Transit beyond Apoptosis. Cancer Research 72: 571–575.
44. Fan P, Agboke FA, McDaniel RE, Sweeney EE, Zou X, et al. (2014) Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. Eur J Cancer 50: 457–468.
45. Goeman JJ, Buhlmann P, (2007) Analyzing gene expression data in terms of gene sets: methodological issues. Bioinformatics 23: 980–987.
46. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, et al. (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355: 560–569.
47. Volinia S, Croce CM, (2013) Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A 110: 7413–7417.
48. Kasprzyk A, (2011) BioMart: driving a paradigm change in biological data management. Database (Oxford) 2011: bar049.
49. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
50. Rudy J, Valafar F, (2011) Empirical comparison of cross-platform normalization methods for gene expression data. Bmc Bioinformatics 12: 467 doi:10.1186/1471-2105-12-467
51. Nishimura D, (2001) BioCarta. Biotech Software & Internet Report 2: 4.
52. Kanehisa M, Goto S, (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27–30.
53. Hastie T, Stuetzle W, (1989) Principal Curves. Journal of the American Statistical Association 84: 502–516.
54. Li JCA, (2003) Modeling survival data: Extending the Cox model. Sociological Methods & Research 32: 117–120.